nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—ABCB1—Parkinson's disease	0.482	1	CbGaD
Naloxone—CREB1—adrenal medulla—Parkinson's disease	0.0379	0.203	CbGeAlD
Naloxone—CREB1—telencephalic ventricle—Parkinson's disease	0.0151	0.0808	CbGeAlD
Naloxone—CREB1—nerve—Parkinson's disease	0.00953	0.051	CbGeAlD
Naloxone—OPRM1—telencephalic ventricle—Parkinson's disease	0.00815	0.0436	CbGeAlD
Naloxone—CREB1—hindbrain—Parkinson's disease	0.00714	0.0382	CbGeAlD
Naloxone—OPRM1—nerve—Parkinson's disease	0.00514	0.0275	CbGeAlD
Naloxone—TLR4—cerebellum—Parkinson's disease	0.00458	0.0245	CbGeAlD
Naloxone—CREB1—embryo—Parkinson's disease	0.00446	0.0239	CbGeAlD
Naloxone—CREB1—brainstem—Parkinson's disease	0.00409	0.0219	CbGeAlD
Naloxone—CREB1—forebrain—Parkinson's disease	0.00395	0.0211	CbGeAlD
Naloxone—TLR4—brain—Parkinson's disease	0.00372	0.0199	CbGeAlD
Naloxone—CREB1—cardiovascular system—Parkinson's disease	0.00334	0.0179	CbGeAlD
Naloxone—OPRD1—forebrain—Parkinson's disease	0.00312	0.0167	CbGeAlD
Naloxone—OPRK1—forebrain—Parkinson's disease	0.00299	0.016	CbGeAlD
Naloxone—CREB1—medulla oblongata—Parkinson's disease	0.00285	0.0153	CbGeAlD
Naloxone—ESR1—hindbrain—Parkinson's disease	0.00281	0.015	CbGeAlD
Naloxone—CREB1—midbrain—Parkinson's disease	0.00261	0.0139	CbGeAlD
Naloxone—CREB1—spinal cord—Parkinson's disease	0.00254	0.0136	CbGeAlD
Naloxone—CREB1—head—Parkinson's disease	0.00226	0.0121	CbGeAlD
Naloxone—OPRM1—brainstem—Parkinson's disease	0.00221	0.0118	CbGeAlD
Naloxone—CREB1—nervous system—Parkinson's disease	0.00214	0.0115	CbGeAlD
Naloxone—OPRM1—forebrain—Parkinson's disease	0.00213	0.0114	CbGeAlD
Naloxone—CREB1—central nervous system—Parkinson's disease	0.00206	0.011	CbGeAlD
Naloxone—CREB1—cerebellum—Parkinson's disease	0.00202	0.0108	CbGeAlD
Naloxone—SLCO1A2—forebrain—Parkinson's disease	0.00183	0.0098	CbGeAlD
Naloxone—OPRD1—head—Parkinson's disease	0.00179	0.00955	CbGeAlD
Naloxone—ESR1—embryo—Parkinson's disease	0.00176	0.0094	CbGeAlD
Naloxone—OPRK1—head—Parkinson's disease	0.00171	0.00916	CbGeAlD
Naloxone—OPRD1—nervous system—Parkinson's disease	0.00169	0.00906	CbGeAlD
Naloxone—CREB1—brain—Parkinson's disease	0.00164	0.00876	CbGeAlD
Naloxone—OPRD1—central nervous system—Parkinson's disease	0.00163	0.00872	CbGeAlD
Naloxone—OPRK1—nervous system—Parkinson's disease	0.00162	0.00869	CbGeAlD
Naloxone—ESR1—brainstem—Parkinson's disease	0.00161	0.00861	CbGeAlD
Naloxone—OPRK1—central nervous system—Parkinson's disease	0.00156	0.00836	CbGeAlD
Naloxone—ESR1—forebrain—Parkinson's disease	0.00155	0.00831	CbGeAlD
Naloxone—OPRK1—cerebellum—Parkinson's disease	0.00153	0.00817	CbGeAlD
Naloxone—OPRM1—midbrain—Parkinson's disease	0.00141	0.00752	CbGeAlD
Naloxone—Methylnaltrexone—CYP2D6—Parkinson's disease	0.00139	0.173	CrCbGaD
Naloxone—OPRM1—spinal cord—Parkinson's disease	0.00137	0.00733	CbGeAlD
Naloxone—SLCO1A2—medulla oblongata—Parkinson's disease	0.00132	0.00708	CbGeAlD
Naloxone—ESR1—cardiovascular system—Parkinson's disease	0.00131	0.00703	CbGeAlD
Naloxone—OPRD1—brain—Parkinson's disease	0.0013	0.00692	CbGeAlD
Naloxone—OPRK1—brain—Parkinson's disease	0.00124	0.00664	CbGeAlD
Naloxone—OPRM1—head—Parkinson's disease	0.00122	0.00652	CbGeAlD
Naloxone—SLCO1A2—midbrain—Parkinson's disease	0.00121	0.00647	CbGeAlD
Naloxone—SLCO1A2—spinal cord—Parkinson's disease	0.00118	0.00631	CbGeAlD
Naloxone—OPRM1—nervous system—Parkinson's disease	0.00116	0.00618	CbGeAlD
Naloxone—OPRM1—central nervous system—Parkinson's disease	0.00111	0.00595	CbGeAlD
Naloxone—SLCO1A2—head—Parkinson's disease	0.00105	0.00561	CbGeAlD
Naloxone—Oxymorphone—CYP2D6—Parkinson's disease	0.00104	0.129	CrCbGaD
Naloxone—SLCO1A2—nervous system—Parkinson's disease	0.000995	0.00532	CbGeAlD
Naloxone—SLCO1A2—central nervous system—Parkinson's disease	0.000958	0.00512	CbGeAlD
Naloxone—SLCO1A2—cerebellum—Parkinson's disease	0.000936	0.00501	CbGeAlD
Naloxone—Hydrocodone—CYP2D6—Parkinson's disease	0.000905	0.113	CrCbGaD
Naloxone—ESR1—head—Parkinson's disease	0.00089	0.00476	CbGeAlD
Naloxone—OPRM1—brain—Parkinson's disease	0.000883	0.00472	CbGeAlD
Naloxone—ESR1—nervous system—Parkinson's disease	0.000844	0.00451	CbGeAlD
Naloxone—Oxycodone—CYP2D6—Parkinson's disease	0.000826	0.103	CrCbGaD
Naloxone—ESR1—central nervous system—Parkinson's disease	0.000812	0.00434	CbGeAlD
Naloxone—ESR1—cerebellum—Parkinson's disease	0.000794	0.00425	CbGeAlD
Naloxone—Buprenorphine—CYP2D6—Parkinson's disease	0.000761	0.0946	CrCbGaD
Naloxone—SLCO1A2—brain—Parkinson's disease	0.000761	0.00407	CbGeAlD
Naloxone—ALB—brain—Parkinson's disease	0.000756	0.00404	CbGeAlD
Naloxone—Hydromorphone—CYP2D6—Parkinson's disease	0.00075	0.0933	CrCbGaD
Naloxone—Naltrexone—ABCB1—Parkinson's disease	0.00074	0.0919	CrCbGaD
Naloxone—ABCB1—embryo—Parkinson's disease	0.000694	0.00371	CbGeAlD
Naloxone—ESR1—brain—Parkinson's disease	0.000645	0.00345	CbGeAlD
Naloxone—Morphine—CYP2D6—Parkinson's disease	0.000638	0.0793	CrCbGaD
Naloxone—ABCB1—forebrain—Parkinson's disease	0.000614	0.00328	CbGeAlD
Naloxone—Buprenorphine—ABCB1—Parkinson's disease	0.000544	0.0676	CrCbGaD
Naloxone—CYP2C8—brain—Parkinson's disease	0.000531	0.00284	CbGeAlD
Naloxone—ABCB1—cardiovascular system—Parkinson's disease	0.000519	0.00278	CbGeAlD
Naloxone—CYP3A4—nervous system—Parkinson's disease	0.000471	0.00252	CbGeAlD
Naloxone—Morphine—ABCB1—Parkinson's disease	0.000455	0.0566	CrCbGaD
Naloxone—CYP3A4—central nervous system—Parkinson's disease	0.000453	0.00242	CbGeAlD
Naloxone—ABCB1—medulla oblongata—Parkinson's disease	0.000444	0.00237	CbGeAlD
Naloxone—ABCB1—midbrain—Parkinson's disease	0.000405	0.00217	CbGeAlD
Naloxone—ABCB1—spinal cord—Parkinson's disease	0.000396	0.00211	CbGeAlD
Naloxone—ABCB1—head—Parkinson's disease	0.000352	0.00188	CbGeAlD
Naloxone—ABCB1—nervous system—Parkinson's disease	0.000333	0.00178	CbGeAlD
Naloxone—ABCB1—central nervous system—Parkinson's disease	0.000321	0.00172	CbGeAlD
Naloxone—ABCB1—cerebellum—Parkinson's disease	0.000314	0.00168	CbGeAlD
Naloxone—ABCB1—brain—Parkinson's disease	0.000255	0.00136	CbGeAlD
Naloxone—CREB1—Signaling Pathways—TAC1—Parkinson's disease	4.9e-05	0.000152	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TAC1—Parkinson's disease	4.89e-05	0.000151	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GCH1—Parkinson's disease	4.87e-05	0.000151	CbGpPWpGaD
Naloxone—ALB—Selenium Micronutrient Network—IL6—Parkinson's disease	4.84e-05	0.00015	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—DRD1—Parkinson's disease	4.81e-05	0.000149	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—HTR2A—Parkinson's disease	4.81e-05	0.000149	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—DRD1—Parkinson's disease	4.79e-05	0.000149	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—HSPA8—Parkinson's disease	4.78e-05	0.000148	CbGpPWpGaD
Naloxone—CREB1—Signaling by NGF—IL6—Parkinson's disease	4.77e-05	0.000148	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—CTGF—Parkinson's disease	4.75e-05	0.000147	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PDYN—Parkinson's disease	4.75e-05	0.000147	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—DRD3—Parkinson's disease	4.66e-05	0.000144	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—CYP2D6—Parkinson's disease	4.65e-05	0.000144	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—EDN1—Parkinson's disease	4.64e-05	0.000144	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—DRD3—Parkinson's disease	4.64e-05	0.000144	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—INSR—Parkinson's disease	4.63e-05	0.000143	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—CTGF—Parkinson's disease	4.57e-05	0.000142	CbGpPWpGaD
Naloxone—TLR4—Immune System—IL6—Parkinson's disease	4.54e-05	0.000141	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—GFAP—Parkinson's disease	4.47e-05	0.000139	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—GRM5—Parkinson's disease	4.42e-05	0.000137	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—FGB—Parkinson's disease	4.37e-05	0.000136	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—FGF20—Parkinson's disease	4.37e-05	0.000135	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—HTR2A—Parkinson's disease	4.36e-05	0.000135	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—HTR1A—Parkinson's disease	4.35e-05	0.000135	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—HSPA1A—Parkinson's disease	4.35e-05	0.000135	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—ADRBK1—Parkinson's disease	4.35e-05	0.000135	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—DBH—Parkinson's disease	4.34e-05	0.000135	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GBA—Parkinson's disease	4.34e-05	0.000135	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—FBP1—Parkinson's disease	4.34e-05	0.000135	CbGpPWpGaD
Naloxone—ALB—Hemostasis—SOD1—Parkinson's disease	4.34e-05	0.000134	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—ADRBK1—Parkinson's disease	4.33e-05	0.000134	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—SLC6A3—Parkinson's disease	4.33e-05	0.000134	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—IL6—Parkinson's disease	4.31e-05	0.000134	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TAC1—Parkinson's disease	4.29e-05	0.000133	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—CYP2E1—Parkinson's disease	4.26e-05	0.000132	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—MAPK8—Parkinson's disease	4.26e-05	0.000132	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ADORA2A—Parkinson's disease	4.24e-05	0.000131	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—EDN1—Parkinson's disease	4.22e-05	0.000131	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—DRD2—Parkinson's disease	4.21e-05	0.000131	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—HTR7—Parkinson's disease	4.21e-05	0.000131	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—NQO1—Parkinson's disease	4.21e-05	0.00013	CbGpPWpGaD
Naloxone—CREB1—Disease—MTHFR—Parkinson's disease	4.21e-05	0.00013	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—DRD1—Parkinson's disease	4.2e-05	0.00013	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—HTR7—Parkinson's disease	4.2e-05	0.00013	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—DRD2—Parkinson's disease	4.2e-05	0.00013	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—CYCS—Parkinson's disease	4.16e-05	0.000129	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—TH—Parkinson's disease	4.15e-05	0.000129	CbGpPWpGaD
Naloxone—ALB—Hemostasis—ABL1—Parkinson's disease	4.14e-05	0.000128	CbGpPWpGaD
Naloxone—ALB—Hemostasis—IGF2—Parkinson's disease	4.12e-05	0.000128	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—DRD3—Parkinson's disease	4.07e-05	0.000126	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—HTR2A—Parkinson's disease	4.06e-05	0.000126	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—CYCS—Parkinson's disease	3.98e-05	0.000123	CbGpPWpGaD
Naloxone—CREB1—Disease—APOE—Parkinson's disease	3.92e-05	0.000121	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—INSR—Parkinson's disease	3.91e-05	0.000121	CbGpPWpGaD
Naloxone—ALB—Hemostasis—HGF—Parkinson's disease	3.89e-05	0.000121	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—Parkinson's disease	3.89e-05	0.00012	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—FGF20—Parkinson's disease	3.88e-05	0.00012	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—TNF—Parkinson's disease	3.81e-05	0.000118	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—ADRBK1—Parkinson's disease	3.8e-05	0.000118	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—SLC6A3—Parkinson's disease	3.79e-05	0.000118	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—ADORA2A—Parkinson's disease	3.76e-05	0.000116	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—FGB—Parkinson's disease	3.7e-05	0.000115	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—HTR2A—Parkinson's disease	3.69e-05	0.000114	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—DRD2—Parkinson's disease	3.68e-05	0.000114	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—HTR7—Parkinson's disease	3.68e-05	0.000114	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—HTR1A—Parkinson's disease	3.68e-05	0.000114	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—DDC—Parkinson's disease	3.66e-05	0.000113	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—CYCS—Parkinson's disease	3.64e-05	0.000113	CbGpPWpGaD
Naloxone—ALB—Metabolism—DDC—Parkinson's disease	3.64e-05	0.000113	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TAC1—Parkinson's disease	3.62e-05	0.000112	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—HMOX1—Parkinson's disease	3.61e-05	0.000112	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—Parkinson's disease	3.57e-05	0.000111	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—DRD1—Parkinson's disease	3.55e-05	0.00011	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IGF2—Parkinson's disease	3.53e-05	0.000109	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ND3—Parkinson's disease	3.53e-05	0.000109	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—MCCC1—Parkinson's disease	3.53e-05	0.000109	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—COMT—Parkinson's disease	3.53e-05	0.000109	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IGF2—Parkinson's disease	3.52e-05	0.000109	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—GSTP1—Parkinson's disease	3.51e-05	0.000109	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—MAOA—Parkinson's disease	3.5e-05	0.000109	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—INSR—Parkinson's disease	3.47e-05	0.000107	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—ABCB1—Parkinson's disease	3.47e-05	0.000107	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—HMOX1—Parkinson's disease	3.46e-05	0.000107	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GSTA4—Parkinson's disease	3.45e-05	0.000107	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—DRD3—Parkinson's disease	3.44e-05	0.000107	CbGpPWpGaD
Naloxone—ALB—Metabolism—GSTA4—Parkinson's disease	3.43e-05	0.000106	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IGF1R—Parkinson's disease	3.41e-05	0.000106	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—Parkinson's disease	3.41e-05	0.000106	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IGF1R—Parkinson's disease	3.4e-05	0.000105	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—GPX1—Parkinson's disease	3.39e-05	0.000105	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—EDN1—Parkinson's disease	3.37e-05	0.000104	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—EDN1—Parkinson's disease	3.36e-05	0.000104	CbGpPWpGaD
Naloxone—CREB1—Disease—INS—Parkinson's disease	3.35e-05	0.000104	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—ABCB1—Parkinson's disease	3.32e-05	0.000103	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—OMD—Parkinson's disease	3.32e-05	0.000103	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—TALDO1—Parkinson's disease	3.32e-05	0.000103	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—FGB—Parkinson's disease	3.28e-05	0.000102	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—HTR1A—Parkinson's disease	3.26e-05	0.000101	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—GSTM1—Parkinson's disease	3.23e-05	0.0001	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ADRBK1—Parkinson's disease	3.21e-05	9.96e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TAC1—Parkinson's disease	3.21e-05	9.95e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—DDC—Parkinson's disease	3.19e-05	9.87e-05	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—HMOX1—Parkinson's disease	3.17e-05	9.81e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—DRD1—Parkinson's disease	3.15e-05	9.76e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NDUFB11—Parkinson's disease	3.14e-05	9.75e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—HTR7—Parkinson's disease	3.11e-05	9.64e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—DRD2—Parkinson's disease	3.11e-05	9.64e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PLA2G6—Parkinson's disease	3.11e-05	9.64e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—NGF—Parkinson's disease	3.1e-05	9.6e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PLA2G6—Parkinson's disease	3.09e-05	9.58e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—GPX1—Parkinson's disease	3.09e-05	9.58e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—NGF—Parkinson's disease	3.09e-05	9.57e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IGF2—Parkinson's disease	3.08e-05	9.56e-05	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—IL6—Parkinson's disease	3.08e-05	9.54e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—MAOB—Parkinson's disease	3.08e-05	9.54e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—MAOB—Parkinson's disease	3.06e-05	9.48e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—DRD3—Parkinson's disease	3.05e-05	9.45e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSTA4—Parkinson's disease	3.01e-05	9.32e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GCH1—Parkinson's disease	3e-05	9.3e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IGF1R—Parkinson's disease	2.98e-05	9.24e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—HTR2A—Parkinson's disease	2.95e-05	9.14e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—EDN1—Parkinson's disease	2.95e-05	9.13e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—HTR2A—Parkinson's disease	2.94e-05	9.11e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	2.93e-05	9.08e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	2.91e-05	9.03e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—MTHFR—Parkinson's disease	2.85e-05	8.84e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—ADRBK1—Parkinson's disease	2.85e-05	8.83e-05	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Parkinson's disease	2.83e-05	8.76e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—HTR7—Parkinson's disease	2.76e-05	8.55e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—DRD2—Parkinson's disease	2.76e-05	8.55e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—APOE—Parkinson's disease	2.74e-05	8.5e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—APOE—Parkinson's disease	2.73e-05	8.47e-05	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—IL6—Parkinson's disease	2.72e-05	8.42e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PLA2G6—Parkinson's disease	2.71e-05	8.39e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—NGF—Parkinson's disease	2.71e-05	8.39e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL1B—Parkinson's disease	2.7e-05	8.38e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—MAOB—Parkinson's disease	2.68e-05	8.31e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GBA—Parkinson's disease	2.67e-05	8.29e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—FBP1—Parkinson's disease	2.67e-05	8.29e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—DBH—Parkinson's disease	2.67e-05	8.29e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—APOE—Parkinson's disease	2.65e-05	8.23e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IGF2—Parkinson's disease	2.61e-05	8.08e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—HTR2A—Parkinson's disease	2.58e-05	7.99e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IGF1R—Parkinson's disease	2.52e-05	7.81e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—EDN1—Parkinson's disease	2.49e-05	7.72e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—MAPK8—Parkinson's disease	2.48e-05	7.68e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—APOE—Parkinson's disease	2.4e-05	7.43e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—INS—Parkinson's disease	2.34e-05	7.26e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—INS—Parkinson's disease	2.34e-05	7.24e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IGF2—Parkinson's disease	2.31e-05	7.16e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NGF—Parkinson's disease	2.29e-05	7.09e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CYP2D6—Parkinson's disease	2.29e-05	7.09e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CYP2D6—Parkinson's disease	2.27e-05	7.05e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—INS—Parkinson's disease	2.27e-05	7.03e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CTGF—Parkinson's disease	2.25e-05	6.96e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IGF1R—Parkinson's disease	2.23e-05	6.93e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CTGF—Parkinson's disease	2.23e-05	6.92e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—EDN1—Parkinson's disease	2.21e-05	6.84e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—HTR2A—Parkinson's disease	2.18e-05	6.75e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CYP2E1—Parkinson's disease	2.09e-05	6.48e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CYP2E1—Parkinson's disease	2.08e-05	6.45e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—NQO1—Parkinson's disease	2.07e-05	6.41e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—NQO1—Parkinson's disease	2.06e-05	6.37e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—INS—Parkinson's disease	2.05e-05	6.35e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—TH—Parkinson's disease	2.04e-05	6.32e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NGF—Parkinson's disease	2.03e-05	6.29e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—TH—Parkinson's disease	2.03e-05	6.28e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—APOE—Parkinson's disease	2.03e-05	6.28e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CYP2D6—Parkinson's disease	1.99e-05	6.18e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—DDC—Parkinson's disease	1.96e-05	6.08e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CYCS—Parkinson's disease	1.96e-05	6.07e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CTGF—Parkinson's disease	1.96e-05	6.06e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CYCS—Parkinson's disease	1.95e-05	6.03e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—HTR2A—Parkinson's disease	1.93e-05	5.99e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTA4—Parkinson's disease	1.85e-05	5.74e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CYP2E1—Parkinson's disease	1.82e-05	5.65e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—NQO1—Parkinson's disease	1.8e-05	5.59e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—APOE—Parkinson's disease	1.8e-05	5.57e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—TH—Parkinson's disease	1.78e-05	5.5e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CASP3—Parkinson's disease	1.74e-05	5.41e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CASP3—Parkinson's disease	1.74e-05	5.39e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—COMT—Parkinson's disease	1.73e-05	5.37e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—IL6—Parkinson's disease	1.73e-05	5.37e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—INS—Parkinson's disease	1.73e-05	5.36e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—IL6—Parkinson's disease	1.73e-05	5.35e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GSTP1—Parkinson's disease	1.73e-05	5.35e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—COMT—Parkinson's disease	1.72e-05	5.34e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—MAOA—Parkinson's disease	1.72e-05	5.33e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GSTP1—Parkinson's disease	1.72e-05	5.32e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—MAOA—Parkinson's disease	1.71e-05	5.3e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CYCS—Parkinson's disease	1.71e-05	5.28e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—HMOX1—Parkinson's disease	1.7e-05	5.27e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—HMOX1—Parkinson's disease	1.69e-05	5.24e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PLA2G6—Parkinson's disease	1.67e-05	5.17e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—MAOB—Parkinson's disease	1.65e-05	5.12e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ABCB1—Parkinson's disease	1.63e-05	5.06e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—ABCB1—Parkinson's disease	1.62e-05	5.03e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MAPK8—Parkinson's disease	1.6e-05	4.97e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MAPK8—Parkinson's disease	1.6e-05	4.95e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GSTM1—Parkinson's disease	1.59e-05	4.91e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL6—Parkinson's disease	1.58e-05	4.91e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GSTM1—Parkinson's disease	1.58e-05	4.89e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—INS—Parkinson's disease	1.53e-05	4.76e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CASP3—Parkinson's disease	1.52e-05	4.72e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GPX1—Parkinson's disease	1.52e-05	4.71e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—IL6—Parkinson's disease	1.51e-05	4.69e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—COMT—Parkinson's disease	1.51e-05	4.68e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GPX1—Parkinson's disease	1.51e-05	4.68e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSTP1—Parkinson's disease	1.5e-05	4.66e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—MAOA—Parkinson's disease	1.5e-05	4.65e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—HMOX1—Parkinson's disease	1.48e-05	4.59e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—IL6—Parkinson's disease	1.46e-05	4.53e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—MTHFR—Parkinson's disease	1.4e-05	4.34e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MAPK8—Parkinson's disease	1.4e-05	4.34e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—MTHFR—Parkinson's disease	1.39e-05	4.32e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSTM1—Parkinson's disease	1.38e-05	4.28e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GPX1—Parkinson's disease	1.32e-05	4.1e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—APOE—Parkinson's disease	1.3e-05	4.04e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—APOE—Parkinson's disease	1.3e-05	4.02e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CASP3—Parkinson's disease	1.29e-05	3.99e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—IL6—Parkinson's disease	1.28e-05	3.97e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP2D6—Parkinson's disease	1.23e-05	3.8e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—MTHFR—Parkinson's disease	1.22e-05	3.78e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CTGF—Parkinson's disease	1.21e-05	3.73e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MAPK8—Parkinson's disease	1.18e-05	3.67e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CASP3—Parkinson's disease	1.14e-05	3.54e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—APOE—Parkinson's disease	1.14e-05	3.52e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP2E1—Parkinson's disease	1.12e-05	3.48e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—INS—Parkinson's disease	1.11e-05	3.45e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NQO1—Parkinson's disease	1.11e-05	3.44e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—INS—Parkinson's disease	1.11e-05	3.43e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—TH—Parkinson's disease	1.09e-05	3.39e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYCS—Parkinson's disease	1.05e-05	3.26e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MAPK8—Parkinson's disease	1.05e-05	3.25e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IL6—Parkinson's disease	1.02e-05	3.17e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IL6—Parkinson's disease	1.02e-05	3.16e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—INS—Parkinson's disease	9.71e-06	3.01e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—COMT—Parkinson's disease	9.3e-06	2.88e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTP1—Parkinson's disease	9.26e-06	2.87e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—MAOA—Parkinson's disease	9.24e-06	2.86e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—HMOX1—Parkinson's disease	9.13e-06	2.83e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL6—Parkinson's disease	8.95e-06	2.77e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ABCB1—Parkinson's disease	8.77e-06	2.72e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTM1—Parkinson's disease	8.51e-06	2.64e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GPX1—Parkinson's disease	8.15e-06	2.53e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL6—Parkinson's disease	7.56e-06	2.34e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—MTHFR—Parkinson's disease	7.52e-06	2.33e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—APOE—Parkinson's disease	7e-06	2.17e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL6—Parkinson's disease	6.7e-06	2.08e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—INS—Parkinson's disease	5.98e-06	1.85e-05	CbGpPWpGaD
